You are here: Home: Audio Program Guide: SABCS 2006 Audio: SABCS 2006
 
  Go to interview with George W Sledge Jr, MD
Go to interview with Norman Wolmark, MD
Go to interview with Clifford Hudis, MD
Go to interview with Julie R Gralow, MD
Go to interview with John F R Robertson, MD
Go to interview with Edith A Perez, MD



 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
George W Sledge Jr, MD
Ballve-Lantero Professor of Oncology
Professor of Medicine and Pathology
Indiana University School of Medicine
Indianapolis, Indiana
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 TAILORx: Hormonal therapy with or without chemotherapy based on the Oncotype DX™ recurrence score
Track 3 ECOG-E5103: Proposed Phase III adjuvant trial of chemotherapy with or without bevacizumab for patients with HER2-negative, node-positive or high-risk node-negative disease
Track 4 ECOG-E2104: Phase II trial of adjuvant dosedense ACpaclitaxel with bevacizumab for node-positive disease
Track 5 Proposed trial concept: Carboplatin/paclitaxel/trastuzumab with or without bevacizumab as first-line therapy for HER2-positive metastatic disease
Track 6 Incorporating lapatinib into future clinical trials

Track 7 XCaliBr: Phase II trial of capecitabine with bevacizumab followed by bevacizumab upon disease progression
Track 8 Potential benefit of involving community-based clinicians in the development of clinical trials
Track 9 Future directions for clinical trials in breast cancer
     
Norman Wolmark, MD
Professor and Chairman
Department of Human Oncology
Allegheny General Hospital
Professor, Drexel University
College of Medicine
Chairman, National Surgical
Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 NSABP-B-38: Phase III adjuvant trial comparing three chemotherapeutic regimens for node-positive, HER2-negative disease
Track 3 NSABP-B-36: Phase III adjuvant trial of six cycles of FEC versus four cycles of AC for patients with node-negative breast cancer
Track 4 NSABP-B-37: Phase III trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer
Track 5 NSABP-B-40: Phase III randomized trial of six neoadjuvant regimens for palpable and operable HER2-negative breast cancer
Track 6 Future NSABP neoadjuvant concept: Trastuzumab versus lapatinib versus the combination for HER2-positive disease

Track 7 Future directions for adjuvant trials in HER2-positive disease
Track 8 NSABP-B-42: Five years of an aromatase inhibitor versus placebo for patients completing five years of an an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor
Track 9 Potential role of trastuzumab and radiation therapy for patients with HER2-positive ductal carcinoma in situ
Track 10 NSABP-P-04: Raloxifene versus an aromatase inhibitor for the prevention of breast cancer
Track 11 NSABP-B-39: Phase III study of whole breast irradiation versus partial breast irradiation for Stage 0, I or II breast cancer
Track 12 TAILORx: Treatment assignment to hormonal therapy with or without chemotherapy based on the Oncotype DX recurrence score
     
Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 CALGB-40101: Phase III randomized study of two schedules of adjuvant cyclophosphamide and doxorubicin versus paclitaxel
Track 3 SWOG-S0221: Randomized trial of four schedules of adjuvant doxorubicin, cyclophosphamide and paclitaxel for node-positive or high-risk node-negative breast cancer
Track 4 CALGB-49907: Adjuvant AC or CMF versus capecitabine for elderly patients
Track 5 Future directions for CALGB clinical trials
Track 6 Potential rationale for and importance of neoadjuvant trials in breast cancer

Track 7 TAILORx: Phase III trial of hormonal therapy with or without adjuvant chemotherapy based on the Oncotype DX recurrence score
Track 8 Ongoing breast cancer clinical trials at Memorial Sloan-Kettering Cancer Center
     
Julie R Gralow, MD
Associate Professor, Medical Oncology
University of Washington and
Fred Hutchinson Cancer Research Center
Seattle, Washington
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 SWOG-S0307: Phase III randomized study of adjuvant zoledronate versus clodronate versus ibandronate
Track 3 Risk of fracture associated with aromatase inhibitors for patients with normal bone density
Track 4 Duration of adjuvant therapy with an aromatase inhibitor
Track 5 SWOG-S0221: Randomized trial of four schedules of adjuvant doxorubicin, cyclophosphamide and paclitaxel
Track 6 Selection of an adjuvant chemotherapeutic regimen

Track 7 SWOG-S0226: Phase III trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for ER-positive metastatic disease
Track 8 Potential role of delayed fulvestrant
Track 9 SWOG-S0511: Phase II trial of goserelin with anastrozole for male patients with ER-positive metastatic or recurrent breast cancer
Track 10 SWOG-S0230: Phase III trial of LHRH analog administration during chemotherapy and following chemotherapy for early-stage, ER-negative, PR-negative disease
Track 11

Future adjuvant trial concepts for patients with HER2-positive disease
     
John F R Robertson, MD
Professor of Surgery
Head of Academic Division of
Breast Surgery
University of Nottingham City Hospital
Nottingham, United Kingdom
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Biologic rationale for potential benefit of combining fulvestrant with an aromatase inhibitor
Track 3 Results of combining anastrozole and tamoxifen in the ATAC trial
Track 4 Ongoing trials evaluating fulvestrant in combination with aromatase inhibitors
Track 5 Combination endocrine therapy in premenopausal patients with ER-positive disease
Track 6 Clinical trial results of high-dose fulvestrant in premenopausal patients

Track 7 Delayed adjuvant fulvestrant after standard endocrine therapy
Track 8 Selection of optimal adjuvant hormonal therapy
Track 9 Changes in perceptions and understanding of endocrine therapy
     
Edith A Perez, MD
Professor of Medicine
Mayo Medical School
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program, Division
of Hematology and Oncology, Mayo Clinic
Jacksonville, Florida
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Impact of adjuvant trastuzumab data on breast cancer management
Track 3 Adjuvant trastuzumab for patients with node-negative disease
Track 4 Results from combined analysis of NCCTGN9831 and NSABP-B-31 trials of adjuvant trastuzumab
Track 5 Current role of adjuvant trastuzumab monotherapy
Track 6 IHC versus FISH to determine HER2 status

Track 7 Potential correlation between cMYC and TOPO II overexpression and response to trastuzumab-based therapies
Track 8 Benefit of concurrent versus sequential administration of chemotherapy and trastuzumab observed in NCCTG-N9831
Track 9 Differences in eligibility criteria and definition of cardiac events among adjuvant trastuzumab trials
Track 10 Incidence of cardiac toxicity with adjuvant chemotherapy and trastuzumab